Stock Events

Supernus Pharmaceuticals 

$25.99
21
-$0.57-2.15% Friday 20:00

Statistics

Day High
26.59
Day Low
25.53
52W High
35.44
52W Low
21.99
Volume
413,875
Avg. Volume
629,534
Mkt Cap
1.43B
P/E Ratio
-90.15
Dividend Yield
-
Dividend
-

Earnings

8MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.29
0.04
0.37
0.7
Expected EPS
0.2625
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SUPN. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap19.05B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing directly with Supernus in the CNS and neurology markets.
Jazz Pharmaceuticals
JAZZ
Mkt Cap7.06B
Jazz Pharmaceuticals focuses on developing and commercializing innovative pharmaceuticals, including for neurological conditions, directly competing with Supernus.
Acadia Pharmaceuticals
ACAD
Mkt Cap2.46B
ACADIA Pharmaceuticals specializes in the development and commercialization of medicines to treat central nervous system disorders, competing in similar markets as Supernus.
Alkermes
ALKS
Mkt Cap4.05B
Alkermes plc is involved in the development and commercialization of pharmaceuticals for CNS diseases, including schizophrenia and depression, areas where Supernus also operates.
Sage Therapeutics
SAGE
Mkt Cap636.73M
Sage Therapeutics is a biopharmaceutical company focused on developing novel medicines to treat life-altering central nervous system disorders, making it a direct competitor.
Neurocrine Biosciences
NBIX
Mkt Cap13.58B
Neurocrine Biosciences develops and markets pharmaceuticals for neurological and endocrine-related diseases and disorders, competing in the same therapeutic areas as Supernus.
AMGEN
AMGN
Mkt Cap163.62B
Amgen, a biotechnology giant, has a diverse portfolio that includes treatments for neurological disorders, indirectly competing with Supernus in some areas.
Biogen
BIIB
Mkt Cap32.82B
Biogen focuses on neurology, and its portfolio includes treatments for multiple sclerosis and spinal muscular atrophy, competing with Supernus in the neurology space.
Abbvie
ABBV
Mkt Cap299.17B
AbbVie has a broad portfolio that includes CNS treatments, such as Parkinson's and Alzheimer's disease medications, making it a competitor in the neurology market.

Analyst Ratings

41$Average Price Target
The highest estimate is $41.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Pharmaceuticals: Other
Manufacturing
Pharmaceutical Preparation Manufacturing
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Show more...
CEO
Jack Khattar
Employees
652
Country
US
ISIN
US8684591089
WKN
000A1JX3U

Listings